Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with
ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.